

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Summary of Consolidated Financial Results For the First Half Ended December 31, 2025 [Japan GAAP]

February 9, 2026

Name of Company: MEDIUS HOLDINGS Co., Ltd.
 Stock Code: 3154 URL: <https://www.mediust.co.jp/>
 Stock Exchange Listing: Tokyo Stock Exchange, Prime Market
 Representative Title: President and Representative Director Name: Yasuhiko Ikeya
 Contact Person Title: Director and General Manager of Corporate Division Name: Hiroyuki Akutagawa
 Phone: +81-(0)3-6811-2958
 Date of filing of semi-annual securities report: February 12, 2026
 Date of commencement of dividend payment: -
 Supplementary explanatory documents: Available
 Earnings presentation: Yes (for institutional investors and analysts)

(Yen in millions, rounded down)

1. Financial results for the first half ended December 2025 (July 1, 2025 – December 31, 2025)

(1) Results of Operations (Consolidated)

(Percentage figures represent year on year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
First half ended Dec. 2025	149,211	4.6	585	(22.1)	817	(16.9)	387	(4.8)
First half ended Dec. 2024	142,704	12.6	751	10.3	983	9.3	406	(19.5)

(Note) Comprehensive income: 1H FY6/26: 243 million yen [(64.1)%] 1H FY6/25: 678 million yen [32.0%]

	Earnings per share		Earnings per share fully diluted	
	Yen		Yen	
First half ended Dec. 2025	17.41		17.39	
First half ended Dec. 2024	18.32		18.32	

(2) Financial Position (Consolidated)

	Total assets	Net assets	Equity ratio
	Million yen	Million yen	%
As of December 31, 2025	127,639	20,285	15.9
As of June 30, 2025	113,024	20,478	18.1

(Reference) Shareholders' equity: As of Dec. 31, 2025: 20,275 million yen

As of Jun. 30, 2025: 20,478 million yen

2. Dividends

	Dividend per share				
	End of 1Q	End of 2Q	End of 3Q	End of FY	Total
FY6/25	Yen —	Yen 0.00	Yen —	Yen 20.00	Yen 20.00
FY6/26	—	0.00	—	—	—
FY6/26 (estimated)	—	—	—	20.00	20.00

(Note) Change in the estimation of dividend from the latest announcement: None

3. Forecast for the fiscal year ending June 2026 (Consolidated, July 1, 2025 - June 30, 2026)

(Percentage figures represent year on year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	305,000	5.6	1,750	(6.7)	2,300	(5.1)	1,300	(5.5)	58.46

(Note) Change in the forecast from the latest announcement: None

* Notes

(1) Significant changes in the scope of consolidation during the period: Yes

Newly included: 1 company (REPS Corp.)

Excluded: 1 company (NOAH INTERNATIONAL co., ltd.)

(Note) For more information, please see "2. Semi-annual Consolidated Financial Statements and Important Notes (4) Notes to semi-annual consolidated financial statements (Changes in the scope of consolidation or the scope of application of the equity method)" on page 12 of Supplementary Information.

(2) Use of accounting methods specifically for the preparation of the semi-annual consolidated financial statements: None

(3) Changes in accounting principles and estimates, and retrospective restatement

(a) Changes in accounting principles due to revision of accounting standards: None

(b) Changes in accounting principles other than in (a): None

(c) Changes in accounting estimates: None

(d) Retrospective restatement: None

(4) Number of shares outstanding (common stock)

(a) Shares outstanding (including treasury shares)

End of 1H FY6/26:	22,238,217	End of FY6/25:	22,238,217
-------------------	------------	----------------	------------

(b) Treasury shares

End of 1H FY6/26:	958	End of FY6/25:	958
-------------------	-----	----------------	-----

(c) Average number of shares outstanding

1H FY6/26:	22,237,259	1H FY6/25:	22,192,390
------------	------------	------------	------------

* Semi-annual financial results reports are exempt from review conducted by certified public accountants or an audit firm.

* Cautionary statement regarding forecasts of operating results and special notes

Forward-looking statements in these materials are based on information available to management at the time this report was prepared and assumptions that management believes are reasonable. Actual results may differ significantly from these statements for a number of reasons. For more information about the forecasts, please see "1. Qualitative Information on Semi-annual Financial Results (3) An explanation of future predictive data, such as consolidated earnings forecasts" on page 4 of Supplementary Information.

Index for Supplementary Information

1. Qualitative Information on Semi-annual Financial Results	2
(1) An explanation of operating results	2
(2) An explanation of financial position	3
(3) An explanation of future predictive data, such as consolidated earnings forecasts.....	4
2. Semi-annual Consolidated Financial Statements and Important Notes	5
(1) Semi-annual consolidated balance sheet.....	5
(2) Semi-annual consolidated statements of income and comprehensive income	7
(Semi-annual consolidated statement of income)	7
(Semi-annual consolidated statement of comprehensive income)	9
(3) Semi-annual consolidated statement of cash flows	10
(4) Notes to semi-annual consolidated financial statements	12
(Notes on going concern assumptions)	12
(Notes on significant change in shareholders' equity).....	12
(Changes in the scope of consolidation or the scope of application of the equity method).....	12
(Notes on segment information, etc.).....	13

1. Qualitative Information on Semi-annual Financial Results

(1) An explanation of operating results

In the environment surrounding the MEDIUS Group during the first half of the current fiscal year, in addition to the 2025 problem, a turning point marked by an increase in the elderly population due to advances in medical technology, there are concerns that the medical system will continue to face intermittent strain as a result of salary increases for medical care professionals, the "Work Style Reform for Doctors" implemented since last year, among other factors. Under these circumstances, medical institutions are called on to build a more efficient medical care supply system through the promotion of medical digital transformation (DX), such as online medical consultations and the application of AI in medical care.

Meanwhile, the outlook for the medical sector remains uncertain, as it continues to face challenges such as rising prices and labor costs, the ongoing depreciation of the yen, increasing interest rates, and the introduction of reciprocal tariffs by the United States on various countries.

In this business environment, the MEDIUS Group is conducting business activities based on the policy of ensuring a stable supply of products while resolving customer issues in order to build a sustainable medical system.

During the first half of the current fiscal year, net sales and gross profit increased compared to the first half of the previous fiscal year, primarily due to an increase in sales following an increase in the number of surgical operations and the acquisition of new customers, mainly in the cardiovascular and orthopedic fields.

Selling, general and administrative expenses increased compared to the first half of the previous fiscal year due to factors such as higher labor costs stemming from personnel hiring and base salary increases associated with business expansion at major subsidiaries, as well as increased outsourcing expenses resulting from higher logistics costs driven by rising distribution prices and higher distribution volumes, among other factors. Due to these circumstances, operating profit, ordinary profit, and profit attributable to owners of parent decreased.

As a result, in the first half of the current fiscal year, net sales increased 4.6% from a year earlier to 149,211 million yen, operating profit decreased 22.1% to 585 million yen, ordinary profit decreased 16.9% to 817 million yen, and profit attributable to owners of parent decreased 4.8% to 387 million yen.

Business segment performance was as follows.

(i) Medical Device

Sales of replacement supplies increased in line with an increase in the number of surgical operations and progress in the acquisition of new customers, mainly in the cardiovascular and orthopedic fields. For medical equipment, although there were sales of large-sized radiotherapy devices and artificial heart-lung machines during the period, net sales declined compared to the first half of the previous fiscal year due mainly to the impact of special demand projects in the same period of the previous fiscal year. Nevertheless, net sales for the segment as a whole increased.

In addition, selling, general and administrative expenses rose due to business expansion, soaring logistics costs, and other factors, resulting in a decrease in segment income.

As a result, net sales increased 4.6% from a year earlier to 146,085 million yen, gross profit increased 2.3% to 16,095 million yen, and segment income (operating profit) decreased 10.5% to 4,510 million yen.

(ii) Welfare Device

Net sales increased due to factors including the accumulation of contracts in the rental business and by maintaining a low cancellation rate. Despite the ongoing surge in costs, gross profit increased, as the high-margin rental business for nursing care equipment performed strongly, among other factors.

In addition, despite rising labor costs, only a moderate rise in selling, general and administrative expenses overall was reported against the increase in gross profit. Accordingly, operating profit increased.

As a result, net sales increased 4.4% from a year earlier to 3,125 million yen, gross profit increased 7.6% to 1,243 million yen, and segment income (operating profit) increased 22.9% to 307 million yen.

(Note) The business segments of the MEDIUS Group consist of the following activities.

Medical Device

(Medical Device Sales Business)

Sale of medical devices (including equipment and replacement supplies) that are purchased from manufacturers, sales agents, trading companies and other companies in Japan to hospitals and other medical institutions in Japan. This is the core business of the MEDIUS Group.

(Medical Device Repair and Maintenance Business)

Repair and after-sales services for medical devices sold by the MEDIUS Group to hospitals and other medical institutions and maintenance services for all medical devices of a hospital or other medical institution based on a maintenance contract.

Welfare Device

Sale of nursing care and welfare products (including equipment and replacement supplies) that are purchased from manufacturers, sales agents, trading companies and other companies in Japan and other countries to hospitals and other medical institutions, nursing care facilities, medical device sales companies, as well as individuals in Japan. This business also rents nursing care and welfare products to individuals.

(2) An explanation of financial position

A. Assets, liabilities, and net assets

(Assets)

Total assets were 127,639 million yen at the end of the first half of the current fiscal year, 14,614 million yen more than at the end of the previous fiscal year.

Current assets increased 15,314 million yen to 104,367 million yen. This increase was mainly the result of increases of 4,915 million yen in cash and deposits, 8,169 million yen in notes and accounts receivable – trade, 1,386 million yen in merchandise and finished goods, and 847 million yen in other current assets, respectively.

Non-current assets decreased 700 million yen to 23,271 million yen. This decrease was mainly the result of decreases of 156 million yen in property, plant and equipment, 270 million yen in intangible assets, and 273 million yen in investments and other assets, respectively.

(Liabilities)

Total liabilities were 107,353 million yen at the end of the first half of the current fiscal year, 14,806 million yen more than at the end of the previous fiscal year.

Current liabilities increased 15,313 million yen to 96,692 million yen. This increase was mainly the result of increases of 7,838 million yen in notes and accounts payable – trade and 8,059 million yen

in short-term borrowings, respectively, despite decreases of 308 million yen in income taxes payable, 114 million yen in provision for bonuses for directors (and other officers), and 165 million yen in other current liabilities, respectively.

Non-current liabilities decreased 507 million yen to 10,660 million yen. This decrease was mainly the result of decreases of 424 million yen in long-term borrowings and 89 million yen in long-term unearned revenue.

(Net assets)

Net assets were 20,285 million yen at the end of the first half of the current fiscal year, 192 million yen less than at the end of the previous fiscal year. This decrease was mainly the result of decreases of 57 million yen in retained earnings and 146 million yen in valuation difference on available-for-sale securities, respectively.

B. Cash flows

Cash and cash equivalents totaled 19,235 million yen at the end of the first half of the current fiscal year, 4,915 million yen more than at the end of the previous fiscal year. The following is a summary of cash flows during the first half of the current fiscal year.

(Operating activities)

Net cash used in operating activities was 1,628 million yen compared with a positive cash flow of 1,482 million yen a year earlier.

Major sources of cash included profit before income taxes of 803 million yen and increase in trade payables of 7,838 million yen, which were outweighed by uses of cash that included increase in trade receivables of 8,185 million yen, increase in inventories of 1,385 million yen, and income taxes paid of 665 million yen.

(Investing activities)

Net cash used in investing activities was 605 million yen compared with 1,366 million yen a year earlier.

Major sources of cash included proceeds from cancellation of insurance funds of 38 million yen, which was outweighed by uses of cash that included purchase of property, plant and equipment of 318 million yen, purchase of intangible assets of 71 million yen, and purchase of long-term prepaid expenses of 237 million yen.

(Financing activities)

Net cash provided by financing activities was 7,148 million yen compared with 586 million yen a year earlier.

Major sources of cash included net increase in short-term borrowings of 8,131 million yen, which outweighed uses of cash that included repayments of long-term borrowings of 495 million yen and dividends paid of 442 million yen.

(3) An explanation of future predictive data, such as consolidated earnings forecasts

There is no change to the consolidated earnings forecast for the fiscal year ending June 30, 2026, which was announced on August 7, 2025.

2. Semi-annual Consolidated Financial Statements and Important Notes

(1) Semi-annual consolidated balance sheet

(Thousand yen)

	Fiscal year ended June 2025 (As of June 30, 2025)	First half ended Dec. 2025 (As of Dec. 31, 2025)
Assets		
Current assets		
Cash and deposits	14,333,767	19,249,684
Notes and accounts receivable - trade	57,988,850	66,158,527
Merchandise and finished goods	13,600,867	14,987,636
Raw materials and supplies	10,963	9,825
Other	3,261,676	4,109,502
Allowance for doubtful accounts	(143,247)	(148,121)
Total current assets	89,052,879	104,367,055
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	7,027,971	6,880,669
Machinery, equipment and vehicles, net	590,856	540,804
Land	3,987,138	3,987,138
Other, net	1,494,317	1,535,620
Total property, plant and equipment	13,100,283	12,944,233
Intangible assets		
Goodwill	1,197,695	1,048,006
Other	1,229,985	1,108,694
Total intangible assets	2,427,681	2,156,700
Investments and other assets		
Other	8,475,332	8,216,660
Allowance for doubtful accounts	(31,196)	(45,638)
Total investments and other assets	8,444,136	8,171,022
Total non-current assets	23,972,100	23,271,956
Total assets	113,024,980	127,639,011

(Thousand yen)

	Fiscal year ended June 2025 (As of June 30, 2025)	First half ended Dec. 2025 (As of Dec. 31, 2025)
Liabilities		
Current liabilities		
Notes and accounts payable - trade	60,110,389	67,948,941
Short-term borrowings	16,755,998	24,815,903
Current portion of bonds payable	8,000	4,500
Income taxes payable	682,884	374,595
Provision for bonuses	62,779	69,121
Provision for bonuses for directors (and other officers)	168,633	54,381
Other	3,590,597	3,425,396
Total current liabilities	81,379,281	96,692,839
Non-current liabilities		
Long-term borrowings	4,471,997	4,047,573
Provision for retirement benefits for directors (and other officers)	157,000	157,000
Provision for share-based payments	21,837	26,370
Provision for loss on guarantees	106,478	121,395
Retirement benefit liability	1,543,990	1,597,939
Asset retirement obligations	162,335	162,537
Long-term unearned revenue	3,114,030	3,024,925
Other	1,589,899	1,522,616
Total non-current liabilities	11,167,568	10,660,357
Total liabilities	92,546,850	107,353,196
Net assets		
Shareholders' equity		
Share capital	1,380,877	1,380,877
Capital surplus	2,879,912	2,879,703
Retained earnings	14,206,045	14,148,626
Treasury shares	(450)	(450)
Total shareholders' equity	18,466,385	18,408,756
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	1,944,633	1,798,534
Remeasurements of defined benefit plans	67,110	68,605
Total accumulated other comprehensive income	2,011,744	1,867,139
Non-controlling interests	-	9,918
Total net assets	20,478,129	20,285,814
Total liabilities and net assets	113,024,980	127,639,011

(2) Semi-annual consolidated statements of income and comprehensive income
 (Semi-annual consolidated statement of income)

(Thousand yen)

	First half ended Dec. 2024 (Jul. 1, 2024 — Dec. 31, 2024)	First half ended Dec. 2025 (Jul. 1, 2025 — Dec. 31, 2025)
Net sales	142,704,820	149,211,026
Cost of sales	125,826,257	131,881,593
Gross profit	16,878,562	17,329,432
Selling, general and administrative expenses		
Provision of allowance for doubtful accounts	9,003	26,156
Provision for share-based payments	1,510	4,439
Salaries and allowances	6,604,342	6,818,799
Employees' bonuses	1,459,622	1,511,628
Provision for bonuses	61,701	77,086
Provision for bonuses for directors (and other officers)	59,441	51,044
Retirement benefit expenses	301,430	310,963
Legal welfare expenses	1,263,780	1,306,659
Depreciation	540,592	544,245
Rent expenses	1,203,433	1,249,033
Outsourcing expenses	1,282,816	1,367,352
Other	3,339,868	3,476,924
Total selling, general and administrative expenses	16,127,543	16,744,333
Operating profit	751,019	585,098
Non-operating income		
Interest income	803	5,183
Dividend income	20,717	25,148
Purchase discounts	164,439	168,469
Reversal of provision for loss on guarantees	270	-
Subsidy income	89,105	89,105
Other	44,426	94,635
Total non-operating income	319,762	382,542
Non-operating expenses		
Interest expenses	74,902	102,741
Provision of allowance for doubtful accounts	-	250
Provision for loss on guarantees	-	14,917
Other	12,684	32,426
Total non-operating expenses	87,586	150,334
Ordinary profit	983,194	817,306
Extraordinary income		
Gain on sale of non-current assets	2,009	6,048
Gain on sale of investment securities	-	66
Total extraordinary income	2,009	6,115
Extraordinary losses		
Loss on sale of non-current assets	131	-
Loss on retirement of non-current assets	1,860	16,361
Impairment losses	-	3,801
Total extraordinary losses	1,992	20,162

(Thousand yen)

	First half ended Dec. 2024 (Jul. 1, 2024 — Dec. 31, 2024)	First half ended Dec. 2025 (Jul. 1, 2025 — Dec. 31, 2025)
Profit before income taxes	983,212	803,258
Income taxes - current	446,893	357,285
Income taxes - deferred	129,567	57,938
Total income taxes	576,460	415,223
Profit	406,751	388,034
Profit attributable to non-controlling interests	-	708
Profit attributable to owners of parent	406,751	387,326

(Semi-annual consolidated statement of comprehensive income)

(Thousand yen)

	First half ended Dec. 2024 (Jul. 1, 2024 — Dec. 31, 2024)	First half ended Dec. 2025 (Jul. 1, 2025 — Dec. 31, 2025)
Profit	406,751	388,034
Other comprehensive income		
Valuation difference on available-for-sale securities	270,811	(146,099)
Remeasurements of defined benefit plans, net of tax	1,243	1,495
Total other comprehensive income	272,054	(144,604)
Comprehensive income	678,805	243,430
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	678,805	242,721
Comprehensive income attributable to non-controlling interests	-	708

(3) Semi-annual consolidated statement of cash flows

(Thousand yen)

	First half ended Dec. 2024 (Jul. 1, 2024 — Dec. 31, 2024)	First half ended Dec. 2025 (Jul. 1, 2025 — Dec. 31, 2025)
Cash flows from operating activities		
Profit before income taxes	983,212	803,258
Depreciation	855,956	920,117
Amortization of goodwill	169,689	149,689
Impairment losses	-	3,801
Increase (decrease) in retirement benefit liability	62,839	56,222
Increase (decrease) in allowance for doubtful accounts	8,697	19,316
Increase (decrease) in provision for bonuses	1,907	6,342
Increase (decrease) in provision for bonuses for directors (and other officers)	(58,236)	(114,251)
Increase (decrease) in provision for share-based compensation	(78,085)	4,532
Interest and dividend income	(21,521)	(30,331)
Interest expenses	74,902	102,741
Share issuance costs	359	-
Loss (gain) on sale of non-current assets	(1,878)	(6,048)
Loss on retirement of non-current assets	1,860	16,361
Loss (gain) on sale of investment securities	-	(66)
Decrease (increase) in trade receivables	(5,596,529)	(8,185,452)
Decrease (increase) in inventories	(855,708)	(1,385,630)
Decrease (increase) in investments in leases	17,304	15,168
Decrease (increase) in other current assets	(510,383)	(846,196)
Increase (decrease) in trade payables	3,456,470	7,838,552
Increase (decrease) in provision for loss on guarantees	(270)	14,917
Subsidy income	(89,105)	(89,105)
Increase (decrease) in accrued consumption taxes	149,506	(197,104)
Increase (decrease) in other current liabilities	(46,906)	5,920
Other, net	50,673	7,020
Subtotal	(1,425,244)	(890,226)
Interest and dividends received	23,564	27,571
Interest paid	(74,897)	(103,662)
Income taxes paid	(536,911)	(665,998)
Income taxes refund	190,699	4,217
Payments of retirement benefits for directors (and other officers)	(2,000)	-
Subsidies received	3,307,093	-
Net cash provided by (used in) operating activities	1,482,304	(1,628,098)

	First half ended Dec. 2024 (Jul. 1, 2024 — Dec. 31, 2024)	First half ended Dec. 2025 (Jul. 1, 2025 — Dec. 31, 2025)
Cash flows from investing activities		
Payments into time deposits	(17,214)	(18,400)
Proceeds from withdrawal of time deposits	43,210	18,000
Purchase of property, plant and equipment	(932,817)	(318,374)
Proceeds from sale of property, plant and equipment	778	10,845
Payments for retirement of property, plant and equipment	(254)	(16,345)
Purchase of intangible assets	(76,578)	(71,201)
Purchase of investment securities	(21,416)	(5,340)
Proceeds from sale of investment securities	-	149
Proceeds from collection of loans receivable	3,366	3,434
Purchase of long-term prepaid expenses	(332,682)	(237,118)
Payments of leasehold and guarantee deposits	(62,765)	(18,976)
Proceeds from refund of leasehold and guarantee deposits	57,519	22,345
Purchase of insurance funds	(14,833)	(16,904)
Proceeds from cancellation of insurance funds	1,230	38,744
Other, net	(14,463)	4,060
Net cash provided by (used in) investing activities	(1,366,922)	(605,081)
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	1,071,000	8,131,000
Proceeds from long-term borrowings	1,000,000	-
Repayments of long-term borrowings	(1,064,150)	(495,519)
Redemption of bonds	-	(3,500)
Proceeds from issuance of shares	71,855	-
Repayments of lease liabilities	(28,015)	(49,458)
Dividends paid	(464,191)	(442,824)
Proceeds from sale of shares of subsidiaries not resulting in change in scope of consolidation	-	9,000
Net cash provided by (used in) financing activities	586,498	7,148,697
Net increase (decrease) in cash and cash equivalents	701,880	4,915,517
Cash and cash equivalents at beginning of period	13,544,776	14,320,367
Increase in cash and cash equivalents resulting from inclusion of subsidiaries in consolidation	42,959	-
Decrease in cash and cash equivalents resulting from change of fiscal term of subsidiaries	(304,947)	-
Cash and cash equivalents at end of period	13,984,668	19,235,884

(4) Notes to Semi-annual consolidated financial statements

(Notes on going concern assumptions)

None

(Notes on significant change in shareholders' equity)

None

(Changes in the scope of consolidation or the scope of application of the equity method)

(Significant changes in the scope of consolidation)

Effective the first half of the current fiscal year, REPS Corp., a new company established on July 1, 2025, has been included in the scope of consolidation of KURIBARA MEDICAL Instruments, which is a consolidated subsidiary of the Company.

Additionally, effective the first half of the current fiscal year, NOAH INTERNATIONAL co., Ltd., formerly a consolidated subsidiary of the Company, has been excluded from the scope of consolidation, as it became an absorbed company in an absorption-type merger, as of October 1, 2025, with Active Medical Co., Ltd., a consolidated subsidiary of the Company, as the surviving company. The surviving company, Active Medical Co., Ltd., as of the same date, has changed its trade name to A. North Medical Inc.

(Notes on segment information, etc.)

[Segment information]

I First half of the previous fiscal year (July 1, 2024 — December 31, 2024)

1. Information about sales and income (loss) by reporting segment

(Thousand yen)

	Reporting segments			Adjustment (Note 1)	Amount on the semi-annual consolidated statement of income (Note 2)
	Medical Device	Welfare Device	Total		
Net sales					
Sales to outside customers	139,709,915	2,994,904	142,704,820	-	142,704,820
Intersegment sales or transfers	9,040	-	9,040	(9,040)	-
Total	139,718,956	2,994,904	142,713,861	(9,040)	142,704,820
Segment income	5,040,007	250,414	5,290,422	(4,539,403)	751,019

(Notes) 1. The 4,539,403 thousand yen negative adjustment for segment income includes 20,663 thousand yen for intersegment transaction eliminations, 169,689 thousand yen deduction for amortization of goodwill, and 4,390,377 thousand yen deduction for corporate expenses that cannot be assigned to specific segments. Corporate expenses are primarily operating expenses of parent company and general and administrative expenses that do not belong to specific segments.

2. The segment income matches operating profit in the semi-annual consolidated statement of income.

II First half of the current fiscal year (July 1, 2025 — December 31, 2025)

1. Information about sales and income (loss) by reporting segment

(Thousand yen)

	Reporting segments			Adjustment (Note 1)	Amount on the semi-annual consolidated statement of income (Note 2)
	Medical Device	Welfare Device	Total		
Net sales					
Sales to outside customers	146,085,333	3,125,692	149,211,026	-	149,211,026
Intersegment sales or transfers	8,564	-	8,564	(8,564)	-
Total	146,093,898	3,125,692	149,219,590	(8,564)	149,211,026
Segment income	4,510,425	307,858	4,818,283	(4,233,184)	585,098

(Notes) 1. The 4,233,184 thousand yen negative adjustment for segment income includes 17,913 thousand yen for intersegment transaction eliminations, 149,689 thousand yen deduction for amortization of goodwill and 4,101,408 thousand yen deduction for corporate expenses that cannot be assigned to specific segments. Corporate expenses are primarily operating expenses of parent company and general and administrative expenses that do not belong to specific segments.

2. The segment income matches operating profit in the semi-annual consolidated statement of income.

2. Information about impairment loss of non-current assets or goodwill by reporting segment

(Important impairment loss of non-current assets)

We are booking impairment loss on non-current assets in the Medical Device segment and the Welfare Device segment. The amount for the first half of the current fiscal year is 3,645 thousand yen for the Medical Device segment and 156 thousand yen for the Welfare Device segment.